A systematic review of clinical guidelines on the management of acute, community-acquired CNS infections by Sigfrid, Louise et al.
RESEARCH ARTICLE Open Access
A systematic review of clinical guidelines
on the management of acute, community-
acquired CNS infections
Louise Sigfrid1*† , Chelsea Perfect2†, Amanda Rojek1, Kajsa-Stina Longuere3, Sam Lipworth4, Eli Harriss5,
James Lee1, Alex Salam6, Gail Carson1, Herman Goossens7 and Peter Horby1
Abstract
Background: The epidemiology of CNS infections in Europe is dynamic, requiring that clinicians have access to up-
to-date clinical management guidelines (CMGs) to aid identification of emerging infections and for improving
quality and a degree of standardisation in diagnostic and clinical management practices. This paper presents a
systematic review of CMGs for community-acquired CNS infections in Europe.
Methods: A systematic review. Databases were searched from October 2004 to January 2019, supplemented by an
electronic survey distributed to 115 clinicians in 33 European countries through the CLIN-Net clinical network of the
COMBACTE-Net Innovative Medicines Initiative. Two reviewers screened records for inclusion, extracted data and
assessed the quality using the AGREE II tool.
Results: Twenty-six CMGs were identified, 14 addressing bacterial, ten viral and two both bacterial and viral CNS
infections. Ten CMGs were rated high quality, 12 medium and four low. Variations were identified in the definition
of clinical case definitions, risk groups, recommendations for differential diagnostics and antimicrobial therapy,
particularly for paediatric and elderly populations.
Conclusion: We identified variations in the quality and recommendations of CMGs for community-acquired CNS
infections in use across Europe. A harmonised European “framework-CMG” with adaptation to local epidemiology
and risks may improve access to up-to-date CMGs and the early identification and management of (re-)emerging
CNS infections with epidemic potential.
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Introduction
Endemic, epidemic and emerging infectious diseases, in-
cluding antimicrobial resistant organisms, remain a ser-
ious, cross-border threat to health in Europe. The
response to these threats needs to be evidence-based
and coordinated, and whilst Europe-wide efforts have
been made to link and harmonise public health re-
sponses, much less has been done in the clinical sphere.
The EU-funded Platform for European Preparedness
Against R(e-)emerging Epidemics (PREPARE) was
established to promote harmonised clinical research
studies on infectious diseases with epidemic potential in
order to improve patient outcomes and inform public
health responses. One issue identified by PREPARE was
the lack of understanding of variations in clinical prac-
tice across Europe, which may hamper the interpretation
of clinical and surveillance data on emerging infectious
threats with epidemic potential and impede the imple-
mentation of cross-border clinical research.
Central nervous system (CNS) infections continue to
affect populations worldwide with high morbidity, mor-
tality and risk of long-term sequelae and are also associ-
ated with a range of emerging and re-emerging viral
threats to Europe, such as West Nile virus, Toscana
virus, measles and enteroviruses [1, 2]. The epidemiology
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of community-acquired CNS infections is neither fixed
nor homogeneous, with changes over time and between
locations. The introduction of vaccines has reduced the
burden of the two most common etiological agents for
bacterial meningitis in adults and older children, Strepto-
coccus pneumoniae and Neisseria meningitidis [3, 4].
Haemophilus influenzae type B (Hib) is also becoming a
rare cause of meningitis in Europe [5]. However, reports
of serotype replacement and an increased rate of re-
duced sensitivity to antimicrobial agents of S. pneumo-
niae, with varying rates across the region, are a cause of
concern, which requires antibiotic regimes to be tailored
to regions and travel [3, 5]. Neonatal meningitis is asso-
ciated with high morbidity and higher incidence com-
pared to older age groups [6]. In neonates, common
pathophysiology are primary bloodstream infections with
secondary haematogenous distribution to the CNS [6]
most commonly caused by Streptococcus agalactiae
(group B streptococcus; GBS) or Escherichia coli [3].
Encephalitis, an inflammation of the brain parenchyma
associated with high morbidity and risk of long-term
sequelae, is commonly caused by viruses [7]. It is
estimated that 40 to 60% of cases remain without an
aetiological diagnosis [8, 9]. This may partly be due to a
lack of consensus on clinical case definitions and
standardised diagnostic approaches [10]. The most
commonly diagnosed causes of viral CNS infections in
Europe are Herpes simplex virus (HSVs), enteroviruses,
Varicella-zoster virus (VZV) and arthropod-borne
viruses (arboviruses) [11]. The epidemiology of ence-
phalitis is constantly evolving [11], and emerging infec-
tious diseases may present as undifferentiated CNS
infections [12]. This is ilustrated by the re-emergence of
West Nile virus (WNV) in south-eastern Europe and the
emergence of Toscana virus as a leading cause of aseptic
meningitis in regions in southern Europe during the
summer [13, 14]. Another cause of concern are recent
outbreaks of enterovirus-associated severe neurological
disease which cause a strain on paediatric intensive care
units [15].
Clinical case definitions and clinical management
guidelines (CMGs) are important tools for identifying
emerging infectious diseases, informing diagnostic and
clinical management and providing a degree of standard-
isation in clinical management practices. In addition,
harmonisation of diagnostic and clinical management
practices can inform public health outbreak responses
and facilitate the design and interpretation of multi-
country research, which is a necessity for adequately
powered studies of comparatively rare diseases such as
CNS infections.
The aim of this review is to identify variations in prac-
tices which might be a barrier to the early identification
and characterisation of emerging CNS infections with
epidemic potential and the implementation of cross-
border clinical research as well as public health re-
sponses. This is, to our knowledge, the first systematic
review and quality appraisal of European CMGs for viral
and bacterial CNS infections.
Methods
The systematic review was completed based on a protocol
registered in the PROSPERO International prospective
register of systematic reviews (ID: CRD42014014212). The
protocol was informed by infectious disease specialists
and systematic reviewers.
Search strategy
One reviewer conducted the first electronic database
search (PubMed, National Guideline Learning Centre,
International Guideline Library, TRIP Database) from
October 2004 to October 2014. Search terms were as
follows: (central nervous system infection [MeSH
Terms]) AND (clinical guideline OR clinical practice
guideline OR physician guideline OR bedside clinical
guideline OR clinical management guideline OR clinical
practice protocol OR physician protocol OR clinical
management protocol) AND (“last 10 years” [PDat]). An
information specialist performed a second updated
electronic search of Ovid MEDLINE, Ovid Embase,
PubMed, TRIP Database and Google using the exploded
thesaurus term “exp Central Nervous System Infections/”,
and the free text terms meningitis, encephalitis, meningo-
encephalitis, combined with a search filter for guidelines
to 22 June 2017.
Search terms:
(“Central Nervous System Infections”[Mesh]) OR men-
ingitis [Title/Abstract]) OR meningoencephalitis [Title/
Abstract]) OR encephalitis [Title/Abstract])) AND
(guideline [Title]) OR guidelines [Title]) OR guidance
[Title]) OR protocol [Title]) OR protocols [Title]) OR
((“Guideline” [Publication Type] OR “Guidelines as
Topic”[Mesh]) OR “Practice Guideline” [Publication
Type])).
TRIP Database and Google were also searched for
“meningitis guideline*”, “encephalitis guideline*” and
“meningoencephalitis guideline*” up to 31 January 2019.
The electronic database searches were supplemented by
searching the references of included CMGs and CMGs
identified through a brief electronic survey which was e-
mailed to 115 clinicians in 33 European countries,
through the CLIN-Net clinical network of the COM-
BACTE-Net Innovative Medicines Initiative [16, 17].
The survey asked clinicians which CMGs they used in
their daily practice to identify and manage patients pre-
senting with syndromes of acute, community-acquired
CNS infections, and asked them to submit the CMGs via
hyperlink or by e-mail. The survey was open from 20
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June to 30 December 2016, with two electronic
reminders.
Eligibility criteria
Two reviewers screened the title, abstract and full-text
guidelines for inclusion. CMGs covering diagnostics
and/or clinical management of suspected community-ac-
quired bacterial or viral CNS infections which were
aimed at or used by clinicians in Europe and published
from 2004 onwards were included. The CMG produced
by Médicins Sans Frontières (MSF) aimed at field set-
tings globally was included, as it could be used in Europe
in emergency situations. There were no language limita-
tions. Guidelines published in non-English languages
were translated using Google Translate and reviewed by
a reviewer with good to excellent knowledge of the lan-
guage. Guidelines that were not aimed at European pop-
ulations were excluded, unless a clinician responding to
the survey reported using them. General antibiotic and
local standard operating policies were excluded. Guide-
lines focused only on patients with specific risk factors,
such as HIV, were excluded.
Data extraction
A standardised form for data extraction covering case
definitions, diagnostic methods, differential diagnostics
and medical management recommendations was devel-
oped. One reviewer extracted data from the CMGs and
a second reviewer checked the data.
Quality appraisal
The CMGs were critically appraised by two reviewers in-
dependently using the Appraisal of Guidelines for Re-
search and Evaluation II (AGREE II) Instrument [18,
19]. The quality was assessed independently by each re-
viewer for six domains: (1) scope and purpose, (2) stake-
holder involvement, (3) rigour of development, (4)
clarity of presentation, (5) applicability and (6) editorial
independence, and through an overall quality score. Ef-
forts were made to find additional information online on
associated webpages for CMGs with limited information
about the methodology used. Within each domain, there
were a number of sub-criteria to score from 1 to 7 (Add-
itional file 1). A score of one was assigned if there was
no information or the criteria was not met; a score of
seven when the criteria were met. These scores were
summarised for each domain, and the total score for the
domain calculated as the percentage of the total possible
score for that domain. The final score for each domain
was calculated as the average of the reviewers’ scores.
Each CMG was also given a total overall quality assess-
ment score based on the average score for all the do-
mains (7 being the highest quality) together with a
recommendation for use with or without further
modifications.
Results
Clinical management guidelines
A total of 26 CMGs covering community-acquired sus-
pected bacterial or viral CNS infections met the inclu-
sion criteria for the review (Fig. 1). The 26 CMGs were
produced in Denmark (n = 2), France (n = 2), Germany
(n = 2), Ireland (n = 1), the Netherlands (n = 1), Norway
(n = 1), Scotland (n = 1), Spain (n = 3), the UK (n = 6),
Europe (n = 3), the USA (n = 3) and MSF (n = 1) (Fig. 2).
Ten focused on viral encephalitis/meningoencephalitis,
14 on bacterial meningitis and two on both
(Additional file 2).
Of the 76 clinicians (n = 76/115, 66%) from 30 Euro-
pean countries who responded to the survey, 29% re-
ported using CMGs produced by US-based, 27% by
national, 23% by local and 14% by European organisa-
tions. There were no national CMGs identified from
those countries where respondents reported using inter-
national CMGs.
Quality appraisal
The overall quality of the CMGs ranged from three to
seven (Table 1). Ten CMGs were assessed as of high
quality (scores 6–7), 12 of medium (scores 4–5) and four
of low quality (score ≤ 3). Six CMGs which focused on
bacterial CNS infections gained the maximum quality
score. Three CMGs scored below 4 and were assessed as
in need of modifications in order to adhere to the
AGREE II guideline development standards [19]. These
modifications included additional information such as
the methodology used to identify evidence and formulate
recommendations, explicit links between evidence and
recommendations and information about stakeholder
engagement and peer review. Wide variations in scores
between CMGs were seen for “rigour of development”.
Seven CMGs scored above 75% for this domain, six of
which covered bacterial [2, 5, 20–24], and one viral [22]
CNS infections. Most CMGs scored well on “clarity of
presentation” and “scope and purpose”. Some score
variations may be due to a lack of information presented,
such as on stakeholder engagement, editorial indepen-
dence and plans for regular revisions. This may partly
explain the general low scores for “applicability” and
“editorial independence”.
Signs and symptoms at presentation
Viral encephalitis/meningoencephalitis
Encephalitis is an inflammation of the brain parenchyma
associated with neurological dysfunction [7, 10], which is
reflected in the syndromic presentation. Meningo-
encephalitis affects both the brain parenchyma and
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meninges [25]. Four of the 12 CMGs covering viral aeti-
ologies described symptoms at presentation in adults [7,
10, 22, 26], four in paediatric populations [7, 10, 27, 28]
and six in unspecified populations [25, 29–33] (Table 2).
Most of the guidelines cited focal neurological signs, sei-
zures, fever, altered levels of consciousness (ALOC) and
changes to personality or behaviour as signs and symp-
toms of encephalitis in both children and adults. It was
noted that objective fever might be lacking at the time of
assessment [10, 26] particularly in immunosuppressed
patients [10].
Bacterial meningitis
Nine CMGs covering bacterial CNS meningitis pre-
sented symptoms at presentation in adults [2, 5, 23, 34–
39], ten in children [5, 20, 21, 23, 24, 34–36, 38, 40],
eight in infants [5, 20, 23, 24, 34, 35, 38, 40] and one in
unspecified populations [31] (Table 2). The classic symp-
toms of fever, headache, neck stiffness, followed by al-
tered mental status and petechial rash, were most
frequently described for adults and older children. How-
ever, for children, there were a wider range of symptoms
reported, with some such as leg pain and cold hands and
feet specifically described in children. The symptoms in
infants and neonates were more general and can be un-
distinguishable from sepsis [20]. Irritability, fever and
poor feeding were most commonly described, followed
by bulging fontanelle, petechial rash and lethargy. It was
also highlighted by several CMGs that although high
fever can be a sign of severity, fever might not always be
present [24, 34], particularly in neonates [5, 23, 24, 40].
This is consistent with the conclusions in the recent
CMG by the European Society for Microbiology and
Infectious Diseases (ESCMID) that, based on evidence
reviews, there are no clinical signs and symptoms that
are present in all children [5]. It was also highlighted
that the classic signs of meningitis are not always
present in adults either [23]. Therefore, bacterial menin-
gitis cannot be ruled out based on the absence of
classical signs and symptoms alone [5].
Diagnostic methods
Viral encephalitis/meningoencephalitis
Encephalitis is generally diagnosed based on a combin-
ation of clinical, laboratory and neuroimaging features
[10, 22]. Cerebrospinal fluid (CSF) investigation with
Fig. 1 PRISMA flowchart
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polymerase chain reaction (PCR) can differentiate
common aetiologies [41–43]. Epidemiological factors
can guide further investigations [22]. Most CMGs
recommended urgent blood and CSF sampling, un-
less lumbar puncture (LP) is contraindicated due to
signs of raised intracranial pressure (ICP) (Table 3).
Magnetic resonance imaging (MRI) was also recom-
mended when possible, or alternatively computed
tomography (CT), since MRI can be useful to detect
early changes and for excluding alternative causes
and is more sensitive and specific compared to CT
[10]. It was highlighted that although some specific
changes on MRI have been associated with certain
aetiological agents (e.g. HSV and arboviruses), it
does not always assist in differentiation and findings
might initially be normal [7]. EEG to aid diagnostics
was mainly recommended for patients displaying
certain symptoms such as altered behaviour or non-
convulsive seizures, to exclude non-infectious
causes [22].
Bacterial meningitis
All CMGs covering bacterial CNS infections recom-
mended urgent LP and most recommended blood sam-
pling (Table 3), since a positive CSF culture is
confirmative of bacterial meningitis and enables in vitro
testing of antimicrobial susceptibility to optimise anti-
biotic treatment, and urgent LP increases diagnostic
chances [5]. If CSF examination is not possible, serum
markers of inflammation and blood cultures, especially if
taken prior to antibiotics, can support the diagnosis and
immunochromatographic antigen testing and PCR can
provide additional information [5]. The CMG by MSF
did not recommend LP for new cases in an epidemic
context when a meningococcal aetiology was confirmed
[38]. Sixty-nine percent (n = 11/16) recommended a CT
Fig. 2 Survey response and national CMG coverage
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Table 1 AGREE II scores
Guidelines Scope and
purpose (%)
Stakeholder
involvement (%)
Rigour of
development (%)
Clarity of
presentation (%)
Applicability
(%)
Editorial
independence (%)
Overall
quality
Viral aetiology
IEC 91.7 63.9 40.6 91.7 52.1 50.0 5
EFNS 83.3 52.8 55.2 91.7 47.9 25.0 5
DNS 38.7 27.7 22.1 41.8 16.6 0.0 3
DGN: VM 69.4 44.4 50.0 75.0 20.8 66.7 5
IDSA 72.2 50.0 58.3 86.1 18.8 83.3 6
PHE: VE 88.9 75.0 44.8 86.1 31.3 50.0 6
BIA: ABN 100 83.3 94.8 94.4 47.9 66.7 6
BIA: ABN/
BPAIIG
100 83.3 74.0 91.7 54.2 0.0 6
AEPED 61.1 33.3 24.0 55.6 20.8 8.3 3
SPILF 78 41.5 45.5 75.0 4.0 8.3 4
Median 80.7 51.4 47.8 86.1 26.1 37.5 5.0
Range (39–100) (22–83) (22–95) (42–94) (17–54) (0–83) (3–6)
Viral and bacterial aetiology
NNF 75.0 52.8 37.5 88.9 6.3 29.2 4
PHE: ME 97.2 69.4 28.1 94.4 43.8 83.3 5
Median 86.1 61.1 32.8 91.7 25.1 56.3 4.5
Range (75–97) (52–69) (28–38) (89–94) (6–44) (29–83) (4–5)
Bacterial aetiology
EFNS 94.4 52.8 47.9 97.2 43.8 0.0 5
ESCMID 100 83.3 88.5 88.9 47.9 66.7 7
DSI 75.0 36.1 20.8 86.1 45.8 0.0 4
SPILF 83.3 38.9 44.8 88.9 25.0 0.0 4
DGN: BM 69.4 44.4 50.0 75.0 20.8 66.7 5
HPSC 100 66.7 45.8 94.4 39.6 0.0 5
NVN 97.2 94.4 87.6 97.2 66.7 29.2 7
MHSSE 100 94.4 90.6 86.1 43.8 50.0 7
NICE 100 86.1 95.8 88.9 79.2 70.8 7
UKJSS 100 88.9 77.1 94.4 47.9 50.0 7
SIGN 91.7 91.7 79.2 86.1 37.5 45.8 7
IDSA 75.0 50.0 59.4 86.1 10.4 54.2 5
AEPED 61.1 33.3 19.8 83.3 20.8 0.0 3
MSF 88.9 47.2 9.4 91.7 50.0 0.0 4
Median 93.1 59.8 54.7 88.9 43.8 37.5 5
Range (61–100) (33–94) (9–96) (75–97) (10–79) (0–71) (3–7)
Abbreviations: IEC International Encephalitis Consortium, EFNS European Federation of Neurological Societies, DNS Dansk Neurologisk Selskab, DGN: VM Deutsche
Gesellschaft für Neurologie: Virale Meningoeczephalitis, PHE: VE Public Health England: Viral Encephalitis, BIA: ABN British Infection Association: Association of
British Neurologists, BPAIIG The British Paediatric Allergy Immunology and Infections Group, AEPED Asociación Española de Pediatría, SPILF Société de Pathologie
Infectieuse de Langue Française, PHE: ME Public Health England: Meningoencephalitis, NNF Norsk Nevrologisk Forening, ESCMID European Society of Clinical
Microbiology and Infectious Diseases, DSI Dansk Selskab for Infektionsmedicin, DGN: BM Deutsche Gesellschaft für Neurologie: Bakterielle Meningoenzephalitis,
HPSC Health Protection Surveillance Centre, NVN Nederlandse Vereniging voor Neurologie, MHSSE Ministry of Health, Social Services and quality, NICE The National
Institute for Health and Care Excellence, UKJSS UK Joint Specialist Societies, SIGN Scottish Intercollegiate Guidelines Network, IDSA Infectious Diseases Society of
America, MSF Médecins Sans Frontières
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scan before LP if clinical signs of raised ICP [2, 5, 23, 31,
34–37, 39, 40, 44]. In contrast, the CMG by NICE stated
that CT is unreliable for identifying raised ICP and
recommended clinical assessment instead of CT [24].
Differential diagnostics
Viral encephalitis/meningoencephalitis
There were wide variations in the differential diagnostic
recommendations for suspected viral CNS infections,
reflecting the many potential causative agents (Table 4).
All CMGs recommended testing for HSV and VZV and
most also for enteroviruses and human immunodefi-
ciency virus (HIV). Fifty percent recommended testing
for parechoviruses [10, 22, 25, 28, 30, 31], with one
CMG specifying only in children [31] and three only in
children under 3 years old [10, 25, 30]. Other CMGs re-
commended testing for Epstein-Barr virus (EBV), human
herpesvirus [6, 7], adenoviruses and, depending on
season or exposure, arboviruses. Testing for influenza,
mumps, measles and rubella were also recommended,
especially during an on-going epidemic [30]. Many, but
not all CMGs provided differential diagnostic tables
based on risk factors, such as age, immune status, travel,
animal contact and seasonality [7, 10, 22, 25, 27–29]. It
was noted by some that PCR, e.g. for HSV, the most
commonly diagnosed aetiological agent, can be falsely
negative, especially in children and early disease course
[10]. If a test is negative and still concerns about the
Table 2 Common signs and symptoms at presentation. The table shows the proportion of CMGs that each specific signs or
symptoms was described in
Bacterial CNS infections
Neonates/infants (≤ 1 year) (n = 8 CMGs) Children (< 16–18 years) (n = 10 CMGs) Adults and unspecified age (n = 10 CMGs)
Signs and symptoms n (%) Signs and symptoms n (%) Signs and symptoms n (%)
Irritability 8 (100) Neck stiffness 10 (100) Fever 10 (100)
Fever 8 (100) Headache 9 (90) Headache 10 (100)
Poor appetite/feeding 8 (100) Fever 9 (90) Neck stiffness 10 (100)
Bulging fontanelle 6 (75) Petechial rash/purpura 8 (80) AMS/ALOC 6 (60)
Petechial rash/purpura 6 (75) AMS 7 (70) Petechial rash/purpura 5 (50)
Lethargy 6 (75) Nausea/vomiting 6 (60) Focal neurological signs 5 (50)
Nausea/vomiting 5 (63) Photophobia 6 (60) Seizures 4 (40)
Neck stiffness 5 (63) Kernig’s sign 5 (50) Photophobia 3 (30)
Seizures 4 (50) Brudzinski’s sign 5 (50) Nausea/vomiting 3 (30)
Apnoea or respiratory distress 4 (50) Cold hands/feet 4 (40)
Hypothermia 4 (50) Abnormal skin colour 4 (40)
Confusion 3 (38) Focal neurological signs 3 (30)
Photophobia 3 (38) Poor appetite 3 (30)
Abnormal skin colour 3 (38) Leg pain 2 (20)
Kernig’s sign 2 (25) Lethargy 2 (20)
Brudzinski’s sign 2 (25) Irritability 2 (20)
Viral CNS infections
Children (n = 4 CMGs) Adults and unspecified age (n = 10 CMGs)
Signs and symptoms n (%) Signs and symptoms n (%)
Seizures 4 (100) Seizures 10 (100)
Focal neurological signs 4 (100) Focal neurological signs 10 (100)
Fever 4 (100) Fever 9 (90)
ALOC 4 (100) ALOC 9 (90)
Changes in personality or behaviour 4 (100) Changes in personality or behaviour 8 (80)
Headache 1 (25) Rash 5 (50)
Headache 4 (40)
Vomiting 1 (10)
Memory changes 1 (10)
Abbreviations: ALOC altered level of consciousness, AMS altered mental status
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diagnosis, it was recommended to take a second CSF
sample within 3 to 7 days [7, 10, 22]; one CMG specified
a minimum of 4 days after onset of neurological
symptoms [26].
Bacterial meningitis
There was consensus on the initial differential diagnos-
tics for adults and older children presenting with syn-
dromes suggestive of bacterial meningitis (Table 5).
Besides two CMGs which only focused on N. meningiti-
dis [20, 21], all recommended testing for N. meningitidis
and S. pneumoniae in adults and children, but with
variations in recommendations for Hib testing. Most
also recommended testing for L. monocytogenes in
adults; four specified for adults over 50 years [5, 31, 39,
44], and one in adults over 60 years [2]. Additional risk
groups for L. monocytogenes were specified as adults
over 18 years old with chronic conditions causing
immunosuppression [2, 5, 25, 36, 39].
The different epidemiology for neonatal meningitis was
reflected in the eight CMGs providing recommendations
for neonates. All recommended testing for GBS, most also
for E. coli (n = 7) and L. monocytogenes (n = 7). There were
variations in the definitions of risk groups for neonates
and infants. The CMG produced by MSF recommended
testing for GBS and Gram-negative bacteria up to 7 days
of age and S. pneumoniae and L. monocytogenes in more
than 7-day-old neonates [38]. Two CMGs recommended
using the neonate recommendations in infants up to 3
months of age [24, 38]. For infants beyond the neonatal
period, most recommended testing for N. meningitidis
(n = 11), S. pneumoniae (n = 10) and Hib (n = 6), again
with variations in the age cut-offs.
Table 3 Diagnostic methods
The table shows the diagnostic methods recommended for patients with suspected viral or bacterial aetiologies. CT should not delay antibiotic treatment for
suspected bacterial meningitis
Abbreviations: IEC International Encephalitis Consortium, EFNS European Federation of Neurological Societies, DNS Dansk Neurologisk Selskab, DGN: VM Deutsche
Gesellschaft für Neurologie: Virale Meningoeczephalitis, PHE: VE Public Health England: Viral Encephalitis, BIA: ABN British Infection Association: Association of
British Neurologists, BPAIIG The British Paediatric Allergy Immunology and Infections Group, AEPED Asociación Española de Pediatría, SPILF Société de Pathologie
Infectieuse de Langue Française, PHE: ME Public Health England: Meningoencephalitis, NNF: Norsk Nevrologisk Forening, ESCMID European Society of Clinical
Microbiology and Infectious Diseases, DSI Dansk Selskab for Infektionsmedicin, DGN: BM Deutsche Gesellschaft für Neurologie: Bakterielle Meningoenzephalitis,
HPSC Health Protection Surveillance Centre, NVN Nederlandse Vereniging voor Neurologie, MHSSE Ministry of Health, Social Services and Equality, NICE The
National Institute for Health and Care Excellence, UKJSS UK Joint Specialist Societies, SIGN Scottish Intercollegiate Guidelines Network, IDSA Infectious Diseases
Society of America, MSF Médecins Sans Frontières, CT computerised tomography, MRI magnetic resonance imaging, EEG electroencephalogram
*Adults only
**Children only
ΔIf MRI unavailable
¤Depending on clinical and epidemiological features
‡Prior to lumbar puncture only if signs of elevated intracranial pressure (ICP)
^If seizures or consciousness disorder
^^If LP contraindicated
Viral encephalitis/meningoencephalitis, Bacterial meningitis
Sigfrid et al. BMC Medicine          (2019) 17:170 Page 8 of 17
Empirical treatment
Viral encephalitis/meningoencephalitis
Although a wide range of viruses can cause CNS in-
fections, the treatment options are limited. Early
treatment using acyclovir (I.V.) pending diagnosis
was recommended by the CMGs focused on viral
CNS infections that included treatment recommen-
dations [7, 22, 26–33] since early treatment with
acyclovir has been associated with a lower risk of
sequelae and death from the most commonly diag-
nosed cause, HSV [7] (Table 6). The recommended
dose for adults or unspecified populations was 10
mg/kg I.V. with a recommended duration varying
from 10 to more than 14 days. A CMG from France
(2017) recommended the addition of amoxicillin in
adults to cover for risk of L. monocytogenes [26]. The dose
for children ranged from 10 to 20mg/kg acyclovir I.V. for
14 to more than 21 days [27, 28], to 20mg/kg I.V. for
Table 4 Diagnostics recommendations for suspected viral encephalitis/meningoencephalitis
CMG Differential diagnostic recommendations
IEC* Children: HSV-1, HSV-2, enteroviruses, EBV, parechovirus (< 3 years), Mycoplasma pneumoniae, TBEV, WNV (S. Europe), TOSV (S. Europe)
Adults: HSV-1, HSV-2, enteroviruses, VZV, Treponema pallidum, Cryptococcus, HIV, TBEV, WNV (S. Europe), TOSV (S. Europe)
Others based on epidemiological and clinical features.
EFNS^ Unspecified: HSV-1, HSV-2, VZV, HHV 6/7, CMV, EBV, JCV, Dengue virus, respiratory viruses, RSV, HIV, adenovirus, influenza A and B,
rotavirus, Coxsackie B5, non-typed enterovirus, Parainfluenza 1 virus
DNS Unspecified: HSV, VZV, HIV, EBV/CMV, syphilis, HHV 6–7, toxoplasma
DGN: VM Unspecified: HSV, VZV, CMV, coxsackievirus, echovirus, adenovirus, phlebovirus, measles, TBE, mumps, EBV, rubella, enterovirus 71, HIV,
parvovirus B19, HHV-6, Dengue virus, FSME, rabies, vaccinia, Lassa virus, Japanese encephalitis, WNV, polioviruses, hantavirus, filovirus
Others based on epidemiological and clinical features.
IDSA* Neonates: HSV 2, CMV, rubella virus, L. monocytogenes, T. pallidum, Toxoplasma gondii
Infants and Children: Eastern equine encephalitis virus, Japanese encephalitis virus, Murray
Valley encephalitis virus, influenza virus, La Crosse virus
Unspecified: HSV, WNV, TBEV, A. phagocytophilum, B.burgdorferi
Elderly: Eastern equine encephalitis virus, St. Louis encephalitis virus, WNV, sporadic Creutzfeldt-Jakob Disease, L. monocytogenes
Person-to-person transmission: VZV, Venezuelan equine encephalitis virus (rare), poliovirus, non-polio enteroviruses, measles virus,
mumps virus, rubella virus, EBV, HHV 6, B virus, WNV (transfusion transplantation, breast feeding), HIV, Nipah virus, rabies virus
(transplantation), influenza virus, M. pneumoniae, Mycobacterium tuberculosis, T. pallidum.
Others based on specific clinical findings, epidemiology and risk factors.
PHE: VE* Children and adults: HSV-1, HSV-2, VZV, enteroviruses, parechovirus (< 3 years), HHV-6 (< 3 years), mumps (if epidemic), Influenza A, B
(if epidemic), HIV,
Others based on specific epidemiology and risk factors
BIA/ABN Adults: HSV-1, HSV-2, VZV, enteroviruses, parechovirus, measles virus, mumps virus, TBEV (eastern Europe), WNV (southern Europe), HIV,
EBV (immunocompromised), CMV (immunocompromised) influenza virus (rare), adenovirus (rare), Erythrovirus B19 (rare), lymphocytic
choreomeningitis virus (rare), rubella virus (rare)
Others based on epidemiological and clinical features.
BIA/ABN/
BPAIIG
Children: HSV-1, HSV-2, VZV, enteroviruses, parechovirus, HHV 6/7, measles virus, mumps virus, rotavirus, HIV, TBEV (eastern Europe),
WNV (southern Europe), HIV, EBV (immunocompromised), CMV (immunocompromised) influenza virus (rare), adenovirus (rare),
Erythrovirus B19 (rare), lymphocytic choreomeningitis virus (rare), rubella virus (rare)
Others based on epidemiological and clinical features.
AEPED* Congenital: Lymphocytic Choriomeningitis virus, CMV, measles virus, T. gondii, T. pallidum,
Neonates (< 1 month): HSV, enteroviruses, adenovirus, Citrobacter spp., GBS, L. monocytogenes
Infants and children > 1month: HSV, enteroviruses, arboviruses, EBV, adenovirus, HIV, M. pneumoniae, Borrelia burgdorferi, Bartonella
henselae, Rickettsia rickettsii.
Others based on epidemiological and clinical features.
SPILF*^ Adults (metropolitan France): HSV, VZV, HIV, enterovirus, L. monocytogenes (higher risk > 65 years), M. tuberculosis (higher risk > 75 years)
NNF* Unspecified: HSV-1, HSV-2, VZV, EBV, HHV-6, enteroviruses, parechovirus (children), adenovirus, Influenza A, measles, mumps, rubella,
HIV, Hepatitis E, Japanese B, WNV, rabies virus, TBE, Eastern equine encephalitis, S. pneumoniae, B. burgdorferi, M. pneumoniae, Chlamydia
trachomatis, L. monocytogenes, M. tuberculosis, cerebral malaria, Cystericosis.
Others based on immune status.
PHE: ME* Unspecified: HIV, HSV-1, HSV-2, VZV, enteroviruses, parechovirus (< 3 years), N. meningitidis, S. pneumoniae, H. influenzae, E. coli, L.
monocytogenes, GBS
Abbreviations: HSV Herpes simplex virus, VZV Varicella-zoster virus, HIV human immunodeficiency virus, HHV human herpesvirus, CMV Cytomegalovirus, EBV
Epstein-Barr virus, RSV respiratory syncytial virus, TBEV tick-borne encephalitis virus, WNV West Nile virus, JEV Japanese encephalitis virus, IEC International
Encephalitis Consortium, EFNS European Federation of Neurological Societies, DNS Dansk Neurologisk Selskab, DGN: VM Deutsche Gesellschaft für Neurologie:
Virale Meningoeczephalitis, PHE: VE Public Health England:Viral Encephalitis, BIA: ABN British Infection Association: Association of British Neurologists, BPAIIG The
British Paediatric Allergy Immunology and Infections Group, AEPED Asociación Española de Pediatría, SPILF Société de Pathologie Infectieuse de Langue Française,
NNF Norsk Nevrologisk Forening, PHE: ME Public Health England: Meningoencephalitis
*Includes non-viral differential diagnostic recommendations
^Differential diagnostic recommendations not clearly defined
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neonates for at least 14 days [27, 28, 32]. It was noted that
treatment and duration should be assessed depending on
additional symptoms and modified depending on diagnos-
tic results.
Bacterial meningitis
All 15 CMGs covering treatment recommended urgent
administration of antibiotics on clinical suspicion of bac-
terial meningitis (Table 7). Thirty-three percent (n = 5/
15) specified a time-frame for administration, ranging
from within one [2, 5] to three [34, 36, 37] hours. Forty-
seven percent (n = 7/15) recommended pre-hospital anti-
biotics if the patient initially presents to a healthcare set-
ting outside of a hospital. One CMG noted that there
are no prospective clinical data on the relationship of
the timing of antimicrobial administration to clinical
outcome in patients with bacterial meningitis, but since
it is a neurologic emergency, appropriate therapy is rec-
ommended as soon as possible after the diagnosis is con-
sidered likely [44]. It was highlighted that the choice of
antibiotics should be informed by risk factors for
different aetiologies, such as age and risk of reduced
susceptibility to penicillin and third-generation
cephalosporins [5]. This was reflected in the CMGs,
though with variations in specification of at-risk groups.
Most recommended a third-generation cephalosporin
alone [5, 34–36, 38, 39, 44] or in combination with a
penicillin for all adults [2, 23, 37], “elderly” [36] and over
50 [5, 39, 44] or over 60 years [2], due to higher risk of
L. monocytogenes infection in these risk groups [5, 34,
36, 39]. Most guidelines that provided recommendations
for neonates recommended a third-generation cephalo-
sporin plus penicillin [5, 20, 23, 24, 35, 38, 40, 44] or
alternatively an aminoglycoside with penicillin [5, 35, 38,
44]. However, the age cut-off for these recommendations
varied, ranging from 1 [5, 23, 44], to 2 [35], or 3 months
of age [20, 24, 38, 40]. For older infants and children,
there was consensus on the recommendations of a third-
generation cephalosporin alone [5, 19–21, 23, 34–36, 38].
The guideline by MSF recommended a cephalosporin
in an epidemic context where N. meningitides is the
most likely pathogen, and addition of cloxacillin if
associated skin or umbilical cord infection for all age-
groups [38].
Many CMGs recommended the addition of vanco-
mycin [2, 5, 34–37, 39, 40] alternatively rifampicin [2,
5, 37, 39] if there is suspicion of reduced sensitivity
to penicillin, except for neonates. However, the CMGs
produced by IDSA (USA) and NICE (UK) gave differ-
ent advice. The first recommended vancomycin to
everyone except neonates (< 28 days old) [44], whereas
the CMG by NICE recommended vancomycin to all
returning travellers or those with recent prolonged or
multiple exposure to antibiotics within the past
3 months, to cover risk of penicillin-resistant strains
of S. pneumoniae [24].
All CMGs focused on bacterial CNS infections re-
commended adjunctive corticosteroids therapy before or
with first dose of antibiotics. Some recommended it up
to a few hours [37], 4 h [5, 39], 12 h [2, 24] or 24 h post-
antibiotics [20, 35]. Four explicitly did not recommend
steroids for patients with immunosuppression [34] or for
neonates [5, 24, 44]. One CMG noted that corticoste-
roids in infants is controversial and only recommended
for Hib meningitis [44]. It was highlighted that cortico-
steroids can reduce inflammation and brain oedema and
Table 6 Empirical treatment recommendations for suspected viral encephalitis and meningoencephalitis
The table shows the CMGs that included recommendations for empirical treatment
Abbreviations: N neonates, P paediatric populations, A adults, NS non-specified population, EFNS European Federation of Neurological Societies, DNS Dansk
Neurologisk Selskab, DGN: VM Deutsche Gesellschaft für Neurologie: Virale Meningoeczephalitis, PHE: VE Public Health England:Viral Encephalitis, BIA: ABN: British
Infection Association: Association of British Neurologists, BPAIIG The British Paediatric Allergy Immunology and Infections Group, AEPED Asociación Española de
Pediatría, SPILF Société de Pathologie Infectieuse de Langue Française, PHE: ME Public Health England: Meningoencephalitis, NNF Norsk Nevrologisk Forening
*Initial empirical treatment recommendations should be reviewed pending diagnostic results
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has in some studies shown benefits of reducing rates of
complications and improving outcomes in patients with
meningitis, but also that some studies have raised
concerns about potential side effects [2].
Discussion
The data highlights the wide range of CMGs for acute,
community-acquired CNS infections in use across Europe
and variations in quality, clinical case definitions for guid-
ing identification and in initial clinical recommendations.
Most CMGs were produced by national or European
organisations. Several survey respondents reported using
CMGs produced by other countries in or outside of
Europe, which may have implications for timely identifi-
cation of causative pathogens and use of antibiotics, unless
they are adapted to regional epidemiology.
Table 7 Empirical treatment recommendations for suspected bacterial meningitis
Initial treatment recommendations*
CMG 3rd-generation
cephalosporin
(ceftriaxone^ or
cefotaxime)
3rd generation-cephalosporin
(ceftriaxone^ or cefotaxime) plus a
penicillin (amoxicillin, ampicillin or
penicillin)
Aminoglycoside
(gentamicin) plus a
penicillin (amoxicillin or
ampicillin)
Add:
glycopeptide
(vancomycin)
Add: corticosteroids
(before or with first
dose of antibiotics)
EFNS
Europe
P, A E Older
children and
adults**
Yes
ESCMID
Europe
P, A N, A > 50 years, or if risk factor for L.
monocytogenes
N **,^ Yes^ up to 4 h post-
antibiotics
DSI
Denmark
A A if risk of L. monocytogenes Yes
SPILF
France
P, A P, A if suspected L. monocytogenes° If S.
pneumoniae
Yes″
DGN: BM
Germany
A A A** Yes
HPSC
Ireland
P > 2m, A N, P < 2 months N, P < 2months **,^ Yes up to 24 h post-
antibiotics
NVN
Netherlands
P, A N, A Yes
MHSSE#
Spain
P Yes
NICE UK P > 3m N, P < 3 months If travel
outside of
the UK
Yes^^ up to 12 h
post-antibiotics
UKJSS UK A A > 60 years Pending
travel history
Yes up to 12 h post-
antibiotics
SIGN#
Scotland
P > 3m N, P ≤ 3 months Yes up to 24 h post-
antibiotics
IDSA USA/
Global
P, A N, A > 50 years N P, A P^, infants if Hib, A
AEPED
Spain
P N, P ≤ 3 months **,^ Yes
MSF Global P > 3m, A N, P ≤ 3 months N, P ≤ 3 months Yes^
NNF
Norway
NS NS Yes
The table shows empirical treatment recommendations for different risk groups
*Initial recommendations to be reviewed as appropriate pending diagnostic results
**If suspicion of reduced sensitivity to penicillin
^Not to neonates
^^Not to infants < 3months
″Not to immunosuppressed
#Focused on N. meningitidis only
Abbreviations: N neonate, P paediatric populations, A adults, E elderly, NS non-specified population, EFNS European Federation of Neurological Societies, ESCMID
European Society of Clinical Microbiology and Infectious Diseases, DSI Dansk Selskab for Infektionsmedicin, SPILF Société de Pathologie Infectieuse de Langue
Française, DGN Deutsche Gesellschaft für Neurologie, BM Bakterielle Meningoenzephalitis, HPSC Health Protection Surveillance Centre, NVN Nederlandse
Vereniging voor Neurologie, MHSSE Ministry of Health, Social Services and Equality, NICE The National Institute for Health and Care Excellence, UKJSS UK Joint
Specialist Societies, SIGN Scottish Intercollegiate Guidelines Network, IDSA Infectious Diseases Society of America, AEPED Asociación Española de Pediatría, MSF
Médecins Sans Frontières, NNF Norsk Nevrologisk Forening
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There were several high-quality CMGs that adhered to
most of the standards set out in the AGREE II tool. All
of the highest scoring CMGs were focused on bacterial
aetiologies. Many were more than 3 years old, which is
the recommended time-frame for re-assessment of valid-
ity [18, 45, 46]. This is a concern in light of the rapidly
changing epidemiology of infections and antimicrobial
resistance. The most recent Europe-wide CMG on bac-
terial meningitis was published in 2016 [5], whilst the
most recent Europe-wide CMG for viral CNS infections
was updated in 2010 [32]. Though there might be
additional CMGs not identified through the review or
survey, this, together with the fact that many survey
respondents used international CMGs, highlights a need
for an updated European-wide CMG covering viral CNS
infections in adult and paediatric populations that can
be adapted nationally.
There was a general consensus on diagnostic methods,
but wider variations in infectious disease differential
diagnostics recommendations, especially for paediatric
and elderly populations. There was also general consen-
sus on the most common bacterial causative agents for
adults and older children, but variations in differential
diagnostic recommendations for infants, neonates and
elderly and in the definitions of these risk groups. This
is illustrated by the different risk groups identified for L.
monocytogenes infection, which in two CMGs were
defined as adults over 50 years [5, 44], whereas over 60
years in another [2]. It is also illustrated by the wide
variations in the definition of risk groups for GBS,
defined as younger than 1 week [38], 28 days [2, 5, 23,
24, 45], 3 months [34, 40] or 24 months [44] in the
recommendations for neonates and infants.
In regard to empirical treatment, there was general
consensus on recommended initial therapy for suspected
viral aetiologies, pending diagnostics. Moreover, there
was a consensus across CMGs on the need for urgent
I.V. antibiotics on clinical suspicion of bacterial meningi-
tis. However, only about half recommended pre-hospital
antibiotics when presenting outside of a hospital setting.
All CMGs recommended a third-generation cephalo-
sporin for suspected bacterial aetiologies, to cover the
most common pathogens in adults and children, but
with variations in recommendations for adding penicillin
to cover L. monocytogenes. Most of the European CMGs
recommended the addition of vancomycin or rifampicin
if decreased susceptibility to penicillin or third-gener-
ation cephalosporin is suspected based on geographical
regions visited, whereas the CMG by NICE recom-
mended it to all returning travellers [24]. The CMG by
IDSA aimed at all global settings recommended vanco-
mycin to everyone beyond neonatal age [44], which
highlights the risk of inappropriate antibiotics usage
unless adapted to regional epidemiology.
Some of the variations in recommendations can be ex-
plained by regional differences in epidemiology and risks
of reduced sensitivity to antimicrobial agents. ECDC
data from 2015 shows wide variations in reduced peni-
cillin resistance rates of S. pneumoniae from 0.6% in
Belgium, to more than 20% in Slovakia, Bulgaria, France,
Spain, Iceland, Poland, Malta and Romania [47]. The
variations in recommendations seen between CMGs
produced in Europe, compared to those produced out-
side of Europe, but used by clinicians in Europe, indicate
risks of inappropriate differential diagnostic requests and
antimicrobial treatment regimes, unless the guidelines
are adapted to national settings. This may lead to de-
layed identification of diseases and inappropriate initial
management. The variations seen in recommendations
for paediatric and elderly populations and the limited
number of CMGs covering these populations also indi-
cate a need to ensure equity in access to CMGs covering
all different at-risk population, as well as region-appro-
priate recommendations.
The review highlights a need for clinicians to ensure
that CMGs are robustly developed, up-to-date and ap-
propriate for the setting and population. In an increas-
ingly global world, it is important to ensure CMGs also
address risks of travel-imported infections. Some
CMGs addressed this by providing tables based on risk
factors [7, 10], or links to websites with up-to-date
international surveillance data and risk assessments
[5], such as the ECDC and the World Health Organiza-
tions websites. This highlights the importance of these
websites to provide current data about the epidemi-
ology of circulating infections and the risk of anti-
biotic-resistant strains globally. Other variations reflect
limitations in the evidence available, such as the defi-
nition of risk groups for infections and effective treat-
ment strategies for these. Furthermore, the limitations
in evidence was also reflected in the variations in r-
ecommended timing of antibiotics and corticosteroids
for bacterial CNS infections, which was also noted in a
recent review [3].
This review highlights important differences in quality,
coverage and initial clinical recommendations between
the CMGs. The AGREE II tool was useful for assessing
the quality of the CMGs. It may be used together with
other tools, such as the 4-item Global Rating Scale
(GRS), but a comparison showed that the GRS is less
sensitive in detecting differences in guideline quality
[48]. There are limitations to the review, in only includ-
ing CMGs which were published or accessible via the
survey, and despite the lack of language restrictions,
most CMGs identified were produced in English or by
EU/EEA member states. Furthermore, the data extrac-
tion was limited to parameters associated with the early
identification and initial management of syndromes of
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community-acquired CNS infections, to assess variations
which could impact on the early identification, manage-
ment and control of emerging infections with epidemic
potential. Antibiotic dosage was not presented, as this is
a clinical decision which may be affected by individual
patient characteristics. The review does not attempt to
create a new guideline, but to highlight important limita-
tions and differences in CMGs in use across Europe,
identifying the need to update recommendations and
harmonise standards in order to inform future research
needs and CMG development.
Despite these limitations, this review highlights varia-
tions in quality and recommendations between the CMGs,
which may be barriers for the rapid identification and
management of CNS infections which may have an impact
on health outcomes and timely identification of emerging
outbreaks. Considering the resources required to develop
complex, evidence-based CMGs, not all health systems
might have the resources required. A “framework-CMG”
produced by an international network of appropriate ex-
perts and stakeholders can provide a useful model for
CMG development, as evident by the high-quality CMGs
identified, some of which have been adopted by clinicians
in several countries. This internationally produced frame-
work CMG would need to address regional risks and
consider resources for regular review, updating and dis-
semination. This model can also improve harmonisation
of case definitions and recommendations, which can facili-
tate equity in access to best available evidence-based rec-
ommendations, rapid identification of emerging infections
and clinical, research and public health responses to epi-
demics. The recent guideline on bacterial CNS infections
produced by ESCMID [5] is a good example of a robust,
comprehensive CMG aimed at a Europe-wide audience,
which can serve as a model to be adapted to regional epi-
demiology as appropriate and monitored for uptake across
the region.
Conclusions
This review highlights variations in the quality and
recommendations of CMGs for community-acquired
CNS infections in use across Europe. A harmonised
European framework-CMG with adaptation to local
epidemiology and risks may improve access to up-to-
date CMGs and the early identification and manage-
ment of (re-) emerging CNS infections with
epidemic potential. The review particularly highlights
the need for an updated European CMG for infec-
tious encephalitis, which covers all risk groups,
including paediatric and elderly populations. Further
research into risk groups for infections and effective
treatment strategies to target these populations is
required.
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